Emerging molecular Therapeutic targets in breast Cancer: Pathologic identification and clinical implications

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Breast carcinoma is a complex disease requiring advanced molecular markers beyond traditional biomarkers (ER, PR, HER2).
• Genomic advances have identified intrinsic subtypes, enabling personalized therapy and improved risk stratification.
• Understanding the tumor microenvironment is crucial for predicting treatment response.

Purpose of the Study:

• To review current and emerging breast cancer biomarkers.
• To highlight their role in advancing precision oncology.
• To discuss challenges and future directions for clinical integration.

Main Methods:

• Review of current literature on breast cancer biomarkers.
• Analysis of established and novel molecular technologies (genomics, next-generation sequencing, liquid biopsy).
• Discussion of high-throughput techniques (spatial transcriptomics, multiplex immunofluorescence).

Main Results:

• Established biomarkers (ER, PR, HER2) are essential but insufficient for full disease complexity.
• Genomic subtypes, cyclin E, BRCA1/2 mutations, and MMR deficiency offer prognostic/predictive value.
• Liquid biopsy and advanced imaging techniques show promise for non-invasive monitoring and biomarker discovery.

Conclusions:

• Novel biomarkers and technologies are crucial for personalized breast cancer treatment.
• Addressing challenges in standardization and validation is key for clinical translation.
• Continued research is essential to integrate new biomarkers and improve patient outcomes.